The American Journal of Managed Care

Overview of CheckMate Trials 648 and 649

CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment. Syma Iqbal, MD: CheckMate 649 was a randomized trial for patients with untreated esophageal GEJ ...
Nasdaq

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic ...
Nasdaq

CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared ...

Opdivo is the first and only PD-1/L1 inhibitor to demonstrate superior first-line efficacy in upper GI cancers across histologies and tumor locations Statistically significant overall survival benefit ...
Pharmabiz

Bristol announces positive results from phase 3 CheckMate -648 trial of Opdivo plus chemotherapy & Opdivo plus Yervoy to treat unresectable advanced or metastatic ESCC

Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...